EGFR-mutant NSCLC cells H1975, SH416, and PC9 were subjected to chronic treatment with 0.5 μM osimertinib (H1975) or 1 μM erlotinib (SH416 and PC9) to generate EGFR TKI-resistant sub-lines, H1975-OR, SH416-ER, and PC9-ER. This evidence concerns the gene EGFR and non-small cell lung carcinoma.